Genmab A/S

Equities

Real-time Estimate Cboe Europe Other stock markets 10:23:03 22/04/2026 BST			5-day change	1st Jan Change
1,777.50 ^DKK	+2.63%		-3.62%	-12.56%

09:25am	ASMI etches in gains... FDJ draws a losing hand
06:19am	BNP Paribas upgrades Genmab to Outperform (Neutral), sets price target at DKK 2,400 - BN	FW

Published on 05/02/2024 at 05:00 pm BST

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Hello, and welcome to the Genmab First Quarter 2024 Conference Call. As a reminder, this conference call is being recorded.

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

09:25am	ASMI etches in gains... FDJ draws a losing hand
06:19am	BNP Paribas upgrades Genmab to Outperform (Neutral), sets price target at DKK 2,400 - BN	FW
05:58am	Nordic Equities in North America - Ericsson Slides 2.2 Percent	FW
05:19am	Goldman Sachs upgrades Genmab to Buy (Neutral), price target DKK 2,200 - BN	FW
04-21	Nordic Equities in North America - Astra Zeneca slips 1.1 percent	FW
04-15	Nordic Equities in North America - Astra Zeneca Gains 0.9 Percent	FW
04-14	Genmab A/S Provides Net Sales of Darzalex Results for the First Quarter of 2026	CI
04-14	Genmab Posts Higher Darzalex Net Sales in Q1	MT
04-14	Genmab Reports Q1 Net Sales of DARZALEX	MT
04-14	Genmab reports Darzalex sales of $3.96 billion in Q1	FW
04-14	Genmab Q1 Darzalex net sales at $3,964 mln	RE
04-14	Jyske Bank upgrades Genmab to Buy from Hold, sets price target at DKK 2,300 - BN	FW
04-14	Genmab Combo Therapy Shows Safe Profile in Ovarian Cancer Trial	MT
04-13	Genmab Says Rinatabart Sesutecan Combination Tolerable in Patients With Advanced Ovarian Cancer	MT
04-13	Genmab reports promising safety data in clinical trial	FW